Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival

Zarah Glad Zimling; Jens Benn Sørensen; Thomas Alexander Gerds; Cecilia Bech; Claus Bøgelund Andersen; Eric Santoni-Rugiu

doi:10.1097/JTO.0b013e318233d6a9

Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival

Zarah Glad Zimling, Jens Benn Sørensen, Thomas Alexander Gerds, Cecilia Bech, Claus Bøgelund Andersen, Eric Santoni-Rugiu

Pathology, Department of

31 Citations (Scopus)

Abstract

The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.

Original language	English
Journal	Journal of Thoracic Oncology
Volume	7
Issue number	1
Pages (from-to)	249-56
Number of pages	8
ISSN	1556-0864
DOIs	https://doi.org/10.1097/JTO.0b013e318233d6a9
Publication status	Published - 2012

Access to Document

10.1097/JTO.0b013e318233d6a9

Cite this

Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. / Zimling, Zarah Glad; Sørensen, Jens Benn; Gerds, Thomas Alexander et al.

In: Journal of Thoracic Oncology, Vol. 7, No. 1, 2012, p. 249-56.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{7c0aa44bd31c4919a7dbfa2100195286,

title = "Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival",

abstract = "The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.",

author = "Zimling, {Zarah Glad} and S{\o}rensen, {Jens Benn} and Gerds, {Thomas Alexander} and Cecilia Bech and Andersen, {Claus B{\o}gelund} and Eric Santoni-Rugiu",

year = "2012",

doi = "10.1097/JTO.0b013e318233d6a9",

language = "English",

volume = "7",

pages = "249--56",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

TY - JOUR

T1 - Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival

AU - Zimling, Zarah Glad

AU - Sørensen, Jens Benn

AU - Gerds, Thomas Alexander

AU - Bech, Cecilia

AU - Andersen, Claus Bøgelund

AU - Santoni-Rugiu, Eric

PY - 2012

Y1 - 2012

N2 - The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.

AB - The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.

U2 - 10.1097/JTO.0b013e318233d6a9

DO - 10.1097/JTO.0b013e318233d6a9

M3 - Journal article

C2 - 22031231

VL - 7

SP - 249

EP - 256

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 1

ER -

Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival

Abstract

Access to Document

Fingerprint

Cite this